Latest Ratios: P/E Ratio 28.6x · EV/EBITDA 24.9x · ROE 16.9%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $9.7B | $10.3B | $7.7B | $6.4B | $5.4B | $4.8B | $4.1B | $2.5B | $2.0B | $1.1B | $1.1B |
| Enterprise Value | $13.4B | $13.9B | $9.2B | $7.8B | $6.6B | $5.8B | $4.9B | $3.8B | $2.2B | $1.4B | $1.3B |
| P/E Ratio → | 28.57 | 29.83 | 25.95 | 30.74 | 23.95 | 24.55 | 23.83 | 23.03 | 21.34 | 26.96 | 21.64 |
| P/S Ratio | 1.93 | 2.03 | 1.82 | 1.72 | 1.78 | 1.82 | 1.69 | 1.25 | 1.12 | 0.69 | 0.65 |
| P/B Ratio | 4.39 | 4.59 | 4.20 | 4.30 | 4.31 | 4.68 | 4.97 | 3.87 | 3.28 | 2.19 | 2.35 |
| P/FCF | 26.29 | 27.66 | 40.95 | 23.78 | 29.09 | 23.19 | 12.59 | 21.05 | 12.70 | 69.47 | 132.23 |
| P/OCF | 17.27 | 18.18 | 22.29 | 17.08 | 19.74 | 17.34 | 10.90 | 13.21 | 9.38 | 15.03 | 14.65 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.75 | 2.17 | 2.09 | 2.19 | 2.20 | 2.06 | 1.88 | 1.25 | 0.86 | 0.79 |
| EV / EBITDA | 24.89 | 25.84 | 20.90 | 23.78 | 18.48 | 18.27 | 17.81 | 21.24 | 16.84 | 15.60 | 10.03 |
| EV / EBIT | 30.88 | 32.06 | 23.45 | 27.75 | 22.27 | 21.83 | 21.79 | 29.03 | 25.14 | 30.52 | 14.08 |
| EV / FCF | — | 37.51 | 48.94 | 28.81 | 35.89 | 28.05 | 15.31 | 31.72 | 14.07 | 86.62 | 159.81 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 13.7% | 13.7% | 15.7% | 15.8% | 17.1% | 17.8% | 17.0% | 14.3% | 12.5% | 10.8% | 11.4% |
| Operating Margin | 8.6% | 8.6% | 8.4% | 6.8% | 9.8% | 9.9% | 9.3% | 6.3% | 4.8% | 2.7% | 5.6% |
| Net Profit Margin | 6.8% | 6.8% | 7.0% | 5.6% | 7.4% | 7.4% | 7.1% | 5.4% | 5.3% | 2.5% | 3.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 16.9% | 16.9% | 17.9% | 15.3% | 19.8% | 21.2% | 23.1% | 17.6% | 16.8% | 8.4% | 11.3% |
| ROA | 6.8% | 6.8% | 6.7% | 5.5% | 7.1% | 7.2% | 6.9% | 6.2% | 8.1% | 3.8% | 5.7% |
| ROIC | 7.0% | 7.0% | 8.7% | 7.1% | 9.8% | 10.5% | 9.2% | 7.0% | 8.0% | 4.4% | 11.8% |
| ROCE | 10.2% | 10.2% | 9.7% | 8.1% | 11.4% | 12.1% | 11.2% | 8.8% | 9.5% | 5.2% | 13.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.86 | 1.86 | 1.07 | 1.25 | 1.26 | 1.24 | 1.36 | 2.05 | 0.40 | 0.63 | 0.62 |
| Debt / EBITDA | 7.72 | 7.72 | 4.46 | 5.71 | 4.38 | 4.00 | 4.01 | 7.47 | 1.87 | 3.57 | 2.17 |
| Net Debt / Equity | — | 1.63 | 0.82 | 0.91 | 1.01 | 0.98 | 1.07 | 1.96 | 0.35 | 0.54 | 0.49 |
| Net Debt / EBITDA | 6.78 | 6.78 | 3.41 | 4.15 | 3.50 | 3.17 | 3.16 | 7.14 | 1.63 | 3.09 | 1.73 |
| Debt / FCF | — | 9.85 | 7.99 | 5.03 | 6.80 | 4.87 | 2.72 | 10.67 | 1.37 | 17.14 | 27.59 |
| Interest Coverage | 54.31 | 54.31 | 47.60 | 34.73 | 33.37 | 38.67 | 24.24 | 8.42 | 5.73 | 3.29 | 13.03 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.42 | 1.42 | 1.56 | 1.42 | 1.34 | 1.22 | 1.04 | 1.20 | 1.29 | 1.63 | 1.58 |
| Quick Ratio | 1.42 | 1.42 | 1.56 | 1.42 | 1.34 | 1.22 | 1.04 | 1.20 | 1.29 | 1.63 | 1.58 |
| Cash Ratio | 0.64 | 0.64 | 0.71 | 0.72 | 0.57 | 0.53 | 0.44 | 0.22 | 0.15 | 0.25 | 0.33 |
| Asset Turnover | — | 0.93 | 0.91 | 0.89 | 0.88 | 0.92 | 0.94 | 0.86 | 1.48 | 1.45 | 1.65 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 45.97 | 48.82 | 47.47 | 49.27 | 45.67 | 46.34 | 55.38 | 52.40 | 60.53 | 53.91 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | 0.2% | 0.3% | 0.4% | 0.5% | 0.8% | 0.8% |
| Payout Ratio | 4.2% | 4.2% | 4.6% | 6.2% | 5.4% | 5.9% | 6.4% | 9.2% | 10.2% | 21.5% | 16.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 3.5% | 3.4% | 3.9% | 3.3% | 4.2% | 4.1% | 4.2% | 4.3% | 4.7% | 3.7% | 4.6% |
| FCF Yield | 3.8% | 3.6% | 2.4% | 4.2% | 3.4% | 4.3% | 7.9% | 4.8% | 7.9% | 1.4% | 0.8% |
| Buyback Yield | 0.2% | 0.2% | 0.0% | 0.0% | 0.6% | 0.2% | 0.6% | 0.3% | 0.1% | 0.7% | 2.8% |
| Total Shareholder Yield | 0.4% | 0.3% | 0.2% | 0.2% | 0.8% | 0.5% | 0.9% | 0.7% | 0.6% | 1.5% | 3.5% |
| Shares Outstanding | — | $59M | $58M | $57M | $57M | $57M | $56M | $56M | $54M | $53M | $52M |
Regulatory reimbursement and staffing
According to current market data, ENSG trades at a forward P/E of 21.57, which appears to command a significant premium over broader healthcare peers, reflecting investor confidence in the company's unique ability to recycle capital through its decentralized cluster model and internal real estate platform.
The current PEG ratio of 2.02 suggests that the market is pricing in sustained, above-average growth, likely driven by the company's track record of successful facility turnarounds. Investors should monitor whether this valuation remains sustainable if the pace of accretive acquisitions slows or if regulatory headwinds compress the margins of the existing portfolio.
Based on reported financial figures, ROIC has remained relatively stable in the 1.9% to 2.3% range over the last ten quarters, suggesting that while the company is successfully deploying capital, the returns on that investment are currently muted by the high fixed-cost nature of the facility base.
The modest ROIC levels indicate that Ensign's growth is capital-intensive, requiring significant ongoing investment to maintain and improve acquired facilities. Analysts should evaluate whether the company can drive higher returns as its regional clusters achieve greater density and operational synergies, or if the current return profile is a structural ceiling for the industry.
As reported in recent quarterly filings, the company's DSO has hovered between 42 and 47 days, indicating a consistent, albeit slow, collection cycle from government and private payers that is characteristic of the post-acute care sector's reliance on complex reimbursement processes.
The stability in DSO suggests that Ensign maintains effective control over its billing and collection functions despite the geographic expansion of its operations. Investors should watch for any meaningful drift in these metrics, as an increase in days sales outstanding could signal potential friction in the reimbursement process or a shift in the payer mix toward slower-paying entities.
According to the most recent balance sheet data, the company has significantly reduced its debt-to-equity ratio to 0.89 in 2026Q1, down from 1.86 in 2025Q4, providing a fortress-like financial position that offers substantial capacity for future acquisitions or defensive maneuvering in volatile markets.
This deleveraging trend is particularly notable given the company's active acquisition strategy, suggesting that Ensign is funding its growth through a disciplined mix of cash flow and equity rather than excessive debt. The low interest coverage ratio, which remains well above 40x, further underscores the company's minimal risk of debt service distress even in a higher interest rate environment.
The P/E ratio is frequently misapplied to Ensign's business model because it fails to account for the significant non-cash depreciation and amortization associated with the company's extensive real estate holdings, which often mask the true underlying cash-generating power of the operational platform.
Investors should instead focus on EV/EBITDA or FCF-based metrics to better capture the value of the company's real estate ownership and its ability to generate cash from its cluster operations. Relying solely on P/E may lead to an undervaluation of the company's long-term asset-backed growth potential and its ability to monetize its property portfolio.
Includes 30+ ratios · 21 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ENSG stock.
The Ensign Group, Inc.'s current P/E ratio is 28.6x. The historical average is 18.9x. This places it at the 89th percentile of its historical range.
The Ensign Group, Inc.'s current EV/EBITDA is 24.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 12.5x.
The Ensign Group, Inc.'s return on equity (ROE) is 16.9%. The historical average is 20.3%.
Based on historical data, The Ensign Group, Inc. is trading at a P/E of 28.6x. This is at the 89th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
The Ensign Group, Inc.'s current dividend yield is 0.15% with a payout ratio of 4.2%.
The Ensign Group, Inc. has 13.7% gross margin and 8.6% operating margin.
The Ensign Group, Inc.'s Debt/EBITDA ratio is 7.7x, indicating high leverage. A ratio above 4x may signal elevated financial risk.